Last month, China's National Health and Family Planning Commission issued updated rules for stem cell clinical trials, offering researchers a clear path for trial approvals. At the same time, the agency warned unscrupulous clinics they will be punished for selling unapproved treatments. Under the new rules, clinical trials must be conducted in Tier IIIa hospitals, records kept for 30 years, an ethics panel must oversee the trial, certified stem cell lines must be used, and patients must be monitored after treatment ends. In addition, patients cannot be charged for treatments administered in a clinical trial. 

(SOURCE: Bio Space)

For more detail of regulation, please visit China NHFPC website Chinese version.

http://www.nhfpc.gov.cn/qjjys/s3581/201508/28635ef99c5743e294f45e8b29c72309.shtml